News
-
-
-
-
PRESS RELEASE
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Tryp Therapeutics, Inc. announces shareholder approval and completion of plan of arrangement with Exopharm Limited. Anticipates trading on ASX as Tryptamine Therapeutics Limited (ticker symbol TYP) in May 2024 -
-
PRESS RELEASE
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Tryp Therapeutics announces securityholders' approval of Arrangement with Exopharm Limited CAN 163 765 991 at annual meeting. Closing expected in late March 2024 -
PRESS RELEASE
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics, Inc. obtains interim court order for proposed arrangement with Exopharm Limited ACN 163 765 991. Meeting scheduled for March 8, 2024, in Toronto, Ontario, to vote on the arrangement resolution -
-
PRESS RELEASE
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Tryp Therapeutics, Inc. announces approval from the Human Research Ethics Committee (HREC) in Australia to start a groundbreaking Phase 1 clinical trial of TRP-8803, an IV-infused psilocin, in healthy human volunteers. The trial aims to optimize doses and infusion rates of IV-administered psilocin to achieve targeted blood levels and will also collect real-time EEG data to monitor changes in EEG patterns associated with the psychedelic state. This milestone is a significant advancement in psychedelic medicine and is expected to provide crucial data for future Phase 2 studies. TRP-8803, a proprietary formulation of psilocin, is anticipated to have faster onset and shorter treatment duration, aiming to treat certain neuropsychiatric disorders with more commercial feasibility. Tryp Therapeutics is also making progress with its TRP-8802 oral psilocybin clinical trial for irritable bowel syndrome patients, with patient dosing expected in the first half of 2024. -
PRESS RELEASE
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Tryp Therapeutics Inc. is pleased to announce the dosing of the first patient in a Phase 2a clinical trial for fibromyalgia using their proprietary IV-infused psilocin, TRP-8802. With positive results, the company aims to further develop TRP-8803 to provide relief to millions of patients suffering from chronic pain. Learn more about Tryp's innovative therapies at www.tryptherapeutics.com.
